Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,174 public posts
Filter results
Why does BAT work in so few?
No one really understood why only 20-30% of
castration
-resistant (CRPC) men derived any benefit and why even that was usually short-lived and didn't increase survival.
No one really understood why only 20-30% of
castration
-resistant (CRPC) men derived any benefit and why even that was usually short-lived and didn't increase survival.
Tall_Allen
in
Advanced Prostate Cancer
2 years ago
A critical review of Provenge. Your inputs welcomed?
We did not find any other
castration
-resistant prostate cancer trials with similarly restrictive enrollment criteria.
We did not find any other
castration
-resistant prostate cancer trials with similarly restrictive enrollment criteria.
GeorgeGlass
in
Advanced Prostate Cancer
2 years ago
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic PCa: 14 Dec 2022.
[/i] [i]
* * *
[/i] [i]
Docetaxel improves overall survival (OS) in
-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired resistance.
[/i] [i]
* * *
[/i] [i]
Docetaxel improves overall survival (OS) in
-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired resistance.
cujoe
in
Fight Prostate Cancer
2 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer ...
While papers on this isolate appear more than a decade ago, the detailed discussion of various mechanisms at play as Pca evolves from
castration
sensitive to
castration
resistant is interesting.
While papers on this isolate appear more than a decade ago, the detailed discussion of various mechanisms at play as Pca evolves from
castration
sensitive to
castration
resistant is interesting.
FRTHBST
in
Advanced Prostate Cancer
2 years ago
No SOC treatment. Metastatic lymph nodes by PSMA-PET. Rising PSA. Bone/CT scans neg. Waiting to die.
I am not eligible (SOC) for other therapies because they all require (by my oncologist, FDA, insurance)
castration
-resistance. My doc says he will prescribe chemo if I choose, which I think I will not. I had a radical prostatectomy early but not radiation or ADT.
I am not eligible (SOC) for other therapies because they all require (by my oncologist, FDA, insurance)
castration
-resistance. My doc says he will prescribe chemo if I choose, which I think I will not. I had a radical prostatectomy early but not radiation or ADT.
maggiedrum
in
Advanced Prostate Cancer
2 years ago
No More Orgovyx, Continuing with Abiraterone and Prednisone
My MO and I have just decided to try the methodology reported in the study titled: "Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic
castration
resistant prostate cancer (mCRPC)".
My MO and I have just decided to try the methodology reported in the study titled: "Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic
castration
resistant prostate cancer (mCRPC)".
rmarkley
in
Advanced Prostate Cancer
2 years ago
olaparib in combination with abiraterone and prednisone
Abiraterone and olaparib for metastatic
castration
-resistant prostate cancer. N Engl J Med. Published online June 3, 2022. doi:10.1056/EVIDoa2200043
Abiraterone and olaparib for metastatic
castration
-resistant prostate cancer. N Engl J Med. Published online June 3, 2022. doi:10.1056/EVIDoa2200043
Graham49
in
Advanced Prostate Cancer
2 years ago
My prostate cancer experience
The oncologist started me on Firmagon, Zytiga and prednisone which had the expected effect of chemical
castration
. My thinking changed and it’s not possible to describe without some reference, the constant clouded mind and poor memory didn’t help my emotional condition.
The oncologist started me on Firmagon, Zytiga and prednisone which had the expected effect of chemical
castration
. My thinking changed and it’s not possible to describe without some reference, the constant clouded mind and poor memory didn’t help my emotional condition.
Lifer69
in
Advanced Prostate Cancer
2 years ago
Prostap (Lupron) Effects
If this had happened over a long period of time I would have put it down to age, but it has happened over a few months so I ascribe it to Prostap and its reductive effect on testosterone i.e. chemical
castration
, but I concede it may be just me.
If this had happened over a long period of time I would have put it down to age, but it has happened over a few months so I ascribe it to Prostap and its reductive effect on testosterone i.e. chemical
castration
, but I concede it may be just me.
Jon1923
in
Advanced Prostate Cancer
2 years ago
AR L702H question
I know this is associated with
castration
resistance but is there other relevant information about what this might mean? Are there trials for this? Does this mean some treatments might not work as well? The psa is 11+ now.
I know this is associated with
castration
resistance but is there other relevant information about what this might mean? Are there trials for this? Does this mean some treatments might not work as well? The psa is 11+ now.
longleaf
in
Advanced Prostate Cancer
2 years ago
Depression from 2nd-generation hormone therapy is worse
I found a JAMA paper on the NIH website titled: Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer It noted that hormone therapy (like first gen Lupron) has a higher incidence of depression as a side effect but that the 2nd-generation meds for
castration
-resistant
I found a JAMA paper on the NIH website titled: Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer It noted that hormone therapy (like first gen Lupron) has a higher incidence of depression as a side effect but that the 2nd-generation meds for
castration
-resistant
maggiedrum
in
Advanced Prostate Cancer
2 years ago
Researchers find novel inhibitors that may suppress oncogenesis of metastatic prostate cancer
In
castration
-resistant prostate cancer, the most aggressive form, cancer cells continue to grow even if testosterone is at or below
castration
levels.
In
castration
-resistant prostate cancer, the most aggressive form, cancer cells continue to grow even if testosterone is at or below
castration
levels.
Scout4answers
in
Advanced Prostate Cancer
2 years ago
Researchers identify a new subtype of castration-resistant prostate cancer (CRPC).
https://www.science.org/doi/10.1126/science.abe1505
https://www.science.org/doi/10.1126/science.abe1505
Scout4answers
in
Advanced Prostate Cancer
2 years ago
COSMIC-021 trial
Cabozantinib plus atezolizumab showed promising antitumour activity in patients with metastatic
castration
-resistant prostate cancer after novel hormonal therapy with an acceptable safety profile, supporting further evaluation of this combination. https://www.thelancet.com/journals/lanonc/article/PIIS1470
Cabozantinib plus atezolizumab showed promising antitumour activity in patients with metastatic
castration
-resistant prostate cancer after novel hormonal therapy with an acceptable safety profile, supporting further evaluation of this combination. https://www.thelancet.com/journals/lanonc/article/PIIS1470
spw1
in
Advanced Prostate Cancer
2 years ago
Lu-177 in Austria - Report and underlining high importance of both FDG and PSMA PET/CTs
Beginning
castration
resistance. 08/2020 until 12/2020, chemoembolization of the prostate (Prof. Vogl, Frankfurt). Tulsa Pro treatment (HIFU) in Alta Klinik Bielefeld 02/2021. Prostate volume reduced to 50ml.
Beginning
castration
resistance. 08/2020 until 12/2020, chemoembolization of the prostate (Prof. Vogl, Frankfurt). Tulsa Pro treatment (HIFU) in Alta Klinik Bielefeld 02/2021. Prostate volume reduced to 50ml.
CurrentSEO
in
Advanced Prostate Cancer
2 years ago
First Follow-Up on Lu-J591 treatment following SBRT
Background: Prospective reports suggest metastasis directed therapy (MDT) in oligometastatic
castration
sensitive prostate cancer (omCSPC) is associated with improved treatment outcomes.
Background: Prospective reports suggest metastasis directed therapy (MDT) in oligometastatic
castration
sensitive prostate cancer (omCSPC) is associated with improved treatment outcomes.
MateoBeach
in
Advanced Prostate Cancer
2 years ago
First Follow Up on my Treatment in Australia
Background: Prospective reports suggest metastasis directed therapy (MDT) in oligometastatic
castration
sensitive prostate cancer (omCSPC) is associated with improved treatment outcomes.
Background: Prospective reports suggest metastasis directed therapy (MDT) in oligometastatic
castration
sensitive prostate cancer (omCSPC) is associated with improved treatment outcomes.
MateoBeach
in
Fight Prostate Cancer
2 years ago
Molecular Characteristics of Patients With mCRPC Achieving Deep Responses to BAT
someone has access to full text Molecular Characteristics of Patients With mCRPC Achieving Deep Responses to BAT Clinical Genitourinary Cancer Save Recommend Share Get Topic Alerts TAKE-HOME MESSAGE This study used data from three IRB-approved clinical trials to identify patients with metastatic
castration
-resistant
someone has access to full text Molecular Characteristics of Patients With mCRPC Achieving Deep Responses to BAT Clinical Genitourinary Cancer Save Recommend Share Get Topic Alerts TAKE-HOME MESSAGE This study used data from three IRB-approved clinical trials to identify patients with metastatic
castration
-resistant
podsart
in
Advanced Prostate Cancer
2 years ago
Avelumab plus SABR encouraging - phase 2 results for mCRPC
Avelumab combined with stereotactic ablative body radiotherapy in metastatic
castration
-resistant prostate cancer: the phase 2 ICE-PAC clinical trial Edmond M Kwan, Lavinia Spain, Angelyn Anton, Chun L Gan, Linda Garrett, Deborah Chang, Elizabeth Liow, Caitlin Bennett, Tiantian Zheng, Jianjun Yu,
Avelumab combined with stereotactic ablative body radiotherapy in metastatic
castration
-resistant prostate cancer: the phase 2 ICE-PAC clinical trial Edmond M Kwan, Lavinia Spain, Angelyn Anton, Chun L Gan, Linda Garrett, Deborah Chang, Elizabeth Liow, Caitlin Bennett, Tiantian Zheng, Jianjun Yu,
Graham49
in
Advanced Prostate Cancer
2 years ago
"A Novel Prognostic Model Predicting Overall Survival in Patients With mCRPC Receiving Standard Chemotherapy"
research: https://www.practiceupdate.com/content/a-novel-prognostic-model-predicting-overall-survival-in-patients-with-mcrpc-receiving-standard-chemotherapy/139044/15/11/1 TAKE-HOME MESSAGE This study aimed to develop a prognostic model to predict the overall survival (OS) of patients with metastatic
castration
-resistant
research: https://www.practiceupdate.com/content/a-novel-prognostic-model-predicting-overall-survival-in-patients-with-mcrpc-receiving-standard-chemotherapy/139044/15/11/1 TAKE-HOME MESSAGE This study aimed to develop a prognostic model to predict the overall survival (OS) of patients with metastatic
castration
-resistant
spouse21
in
Advanced Prostate Cancer
2 years ago
1
...
15
16
17
...
59
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1043 results
Fight Prostate Cancer
75 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest